Free Trial
→ I'm handing you this one free (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$296.68
+0.6%		$274.15
$190.75
▼
$302.93
$524.95B0.26.30 million shs1.27 million shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$170.53
+0.5%		$154.40
$116.88
▼
$176.58
$211.77B0.356.80 million shs1.56 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$149.03
+1.3%		$146.34
$90.90
▼
$156.92
$367.71B0.1310.56 million shs2.49 million shs
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$405.14
+0.5%		$391.12
$255.96
▼
$461.62
$363.00B0.517.18 million shs1.20 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
+0.36%+0.27%+5.01%+17.41%+31.05%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-0.67%-2.72%+12.83%+22.87%+38.49%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-0.49%-1.94%+1.23%+8.63%+62.00%
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
-0.43%-1.59%+6.66%+0.96%+23.30%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$296.68
+0.6%		$274.15
$190.75
▼
$302.93
$524.95B0.26.30 million shs1.27 million shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$170.53
+0.5%		$154.40
$116.88
▼
$176.58
$211.77B0.356.80 million shs1.56 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$149.03
+1.3%		$146.34
$90.90
▼
$156.92
$367.71B0.1310.56 million shs2.49 million shs
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$405.14
+0.5%		$391.12
$255.96
▼
$461.62
$363.00B0.517.18 million shs1.20 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
+0.36%+0.27%+5.01%+17.41%+31.05%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-0.67%-2.72%+12.83%+22.87%+38.49%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-0.49%-1.94%+1.23%+8.63%+62.00%
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
-0.43%-1.59%+6.66%+0.96%+23.30%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.83
Moderate Buy$297.46-0.04% Downside
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.79
Moderate Buy$171.070.24% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.59
Moderate Buy$155.744.45% Upside
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
2.71
Moderate Buy$463.9314.48% Upside

Current Analyst Ratings Breakdown

Latest ABBV, MRK, GILD, and UNH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/12/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Argus logo
Argus
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$190.00
11/4/2026
AbbVie Inc. stock logo
ABBV
AbbVie
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$315.00
11/4/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$196.00
11/3/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Argus logo
Argus
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageStrong-Buy
11/3/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
DZ Bank AG logo
DZ Bank
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy ➝ Hold$153.00
11/2/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingMarket Perform$275.00
11/2/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$288.00 ➝ $322.00
11/2/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOutperform$175.00
11/2/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$300.00 ➝ $340.00
11/2/2026
AbbVie Inc. stock logo
ABBV
AbbVie
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$275.00 ➝ $295.00
11/2/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOutperform$309.00 ➝ $342.00
(Data available from 11/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$61.16B8.60$15.34 per share19.40($2.57) per share-115.79
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$29.44B7.19$10.46 per share16.32$10.44 per share16.35
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.01B5.65$11.51 per share12.96$18.23 per share8.18
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$449.66B0.81$21.26 per share19.06$116.21 per share3.49
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.23B$5.8151.2018.581.3415.67%-450.55%16.50%N/A
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$8.51B-$3.16N/A16.91N/A-12.47%-1.85%-0.61%N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$0.97153.5616.426.793.64%16.73%5.88%N/A
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$12.06B$17.5123.1517.331.473.53%17.95%5.95%1/20/2027 (Estimated)

Latest ABBV, MRK, GILD, and UNH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/30/2026Q3 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$3.73$3.82+$0.09$2.37$17.32 billion$17.40 billion
10/29/2026Q3 2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$2.19$2.55+$0.36$1.94$7.81 billion$8.30 billion
10/29/2026Q3 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.09$2.49+$0.40$2.04$17.33 billion$18.09 billion
10/13/2026Q3 2026
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$4.14$4.69+$0.55$4.56$111.31 billion$112.72 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.922.33%+6.80%119.10%53 Years
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.281.92%+3.04%N/A 10 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.402.28%+5.75%350.52%14 Years
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
$9.282.29%+12.57%53.00%15 Years

Latest ABBV, MRK, GILD, and UNH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/29/2026
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.822.47%1/15/20271/15/20272/16/2027
10/27/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
quarterly$0.821.98%12/15/202612/15/202612/30/2026
11/3/2026
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
quarterly$2.322.27%12/7/202612/7/202612/15/2026
9/10/2026
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.732.44%10/15/202610/15/202611/16/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
N/A
0.87
0.75
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.84
1.38
1.22
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.11
1.35
1.14
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
0.66
0.74
0.74

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
87.86%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.06%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.30%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
0.19%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
57,0001.77 billion1.77 billionOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,0001.24 billion1.24 billionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.46 billionOptionable
UnitedHealth Group Incorporated stock logo
UNH
UnitedHealth Group
390,000896.02 million894.32 millionOptionable

Recent News About These Companies

Why Is UnitedHealth (UNH) Up 1.9% Since Last Earnings Report?
 |  zacks.comhttps://www.zacks.com/stock/news/3028854/why-is-unitedhealth-unh-up-1-9-since-last-earnings-report?cid=cs-stocknewsapi-ft-realtime_blog-3028854
Did UnitedHealth Group Incorporated Insiders Breach their Fiduciary Duties to Shareholders?
 |  prnewswire.comhttps://www.prnewswire.com/news-releases/did-unitedhealth-group-incorporated-insiders-breach-their-fiduciary-duties-to-shareholders-302938085.html
Assorted pharmaceutical pills, a medicine vial, and a syringe arranged on a laboratory bench.
3 Pharmaceutical Stocks That Offer Safety and Growth (UNH)
...
 |  marketbeat.comhttps://www.marketbeat.com/articles/3-pharmaceutical-stocks-that-offer-safety-and-growth/
Do Wall Street Analysts Like UnitedHealth Group Stock?
 |  barchart.comhttps://www.barchart.com/story/news/8799883/do-wall-street-analysts-like-unitedhealth-group-stock
Is it Too Late to Buy UnitedHealth Stock?
November 12 at 7:30 AM  |  fool.comhttps://www.fool.com/investing/2026/11/12/is-it-too-late-to-buy-unitedhealth-stock/
Maryland State Retirement & Pension System Makes New Investment in UnitedHealth Group Incorporated $UNH
November 12 at 6:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-maryland-state-retirement-pension-system-makes-new-investment-in-unitedhealth-group-incorporated-unh-2026-11-12/
UnitedHealth adds children’s hospital executive to board
November 11 at 12:46 PM  |  healthcaredive.comH
UnitedHealth Just Raised Guidance for the Third Time This Year. Where Will the Stock Be in 3 Years?
November 11 at 7:45 AM  |  fool.comhttps://www.fool.com/investing/2026/11/11/unitedhealth-just-raised-guidance-for-the-third-ti/
UnitedHealth Group (UNH) Will Drop Medicare Plans In 140 Counties And Leave Wyoming
November 10 at 8:14 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/unitedhealth-group-unh-drop-medicare-001646439.html
UnitedHealth Group (NYSE:UNH) Shares Climb 1.8% - Here's What Happened
November 10 at 5:20 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-unitedhealth-group-nyse-unh-shares-climb-18-heres-what-happened-2026-11-10/
UnitedHealth Group Incorporated $UNH Position Raised by Red Cedar Investment Management LLC
November 10 at 6:35 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-unitedhealth-group-incorporated-unh-position-raised-by-red-cedar-investment-management-llc-2026-11-10/
UnitedHealth Group Incorporated $UNH Stock Purchased by Kinsale Capital Group Inc.
November 10 at 6:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-unitedhealth-group-incorporated-unh-stock-purchased-by-kinsale-capital-group-inc-2026-11-10/
5,610 UnitedHealth Group Incorporated $UNH Shares Sold by Lockheed Martin Investment Management Co.
November 10 at 6:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-5610-unitedhealth-group-incorporated-unh-shares-sold-by-lockheed-martin-investment-management-co-2026-11-10/
UnitedHealth Group Incorporated $UNH Stock: M&G PLC Decreases Holdings
November 10 at 5:56 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-unitedhealth-group-incorporated-unh-stock-mg-plc-decreases-holdings-2026-11-10/
Retirement Systems of Alabama Purchases 267,068 Shares of UnitedHealth Group Incorporated $UNH
November 10 at 5:40 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-retirement-systems-of-alabama-purchases-267068-shares-of-unitedhealth-group-incorporated-unh-2026-11-10/
UnitedHealth Group Incorporated $UNH Shares Purchased by Allspring Global Investments Holdings LLC
November 10 at 3:09 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-unitedhealth-group-incorporated-unh-shares-purchased-by-allspring-global-investments-holdings-llc-2026-11-10/
Q3 Earnings Season Winners: 3 Companies Raising Guidance
November 9 at 9:15 PM  |  zacks.comhttps://www.zacks.com/stock/news/3026859/q3-earnings-season-winners-3-companies-raising-guidance?cid=cs-stocknewsapi-ft-stocks_in_the_news-3026859
UnitedHealth Group (UNH) Stock Price Prediction: Bernstein target stands over neutral momentum as Binance positioning leans modestly long
November 9 at 6:53 PM  |  blockchain.newsB
Madeline Bell Joins UnitedHealth Group Board of Directors
November 9 at 6:53 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/madeline-bell-joins-unitedhealth-group-212500643.html
UnitedHealth Appoints Madeline Bell as Independent Director
November 9 at 5:51 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/unitedhealth-appoints-madeline-bell-as-independent-director?utm_source=marketbeat.com&utm_medium=referral
Madeline Bell Joins UnitedHealth Group Board of Directors
November 9 at 4:25 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20261109378251/en/madeline-bell-joins-unitedhealth-group-board-of-directors/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbbVie logo over a laboratory scene with vials, a pipette, and a DNA helix illustration.
AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another Test
By Thomas Hughes | November 2, 2026
3 Dividend Stocks That Could Pay You No Matter Who Wins the Midterms
3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach
By Bridget Bennett | October 23, 2026
A home office desk with a laptop displaying a Daily Market Pulse financial report, beside a coffee mug and notebook.
MarketBeat Week in Review – 11/2 - 11/6
By MarketBeat Staff | November 7, 2026
Vaccine vial and syringe on a lab surface with DNA strands and virus particle illustrations in the background.
Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid?
By Chris Markoch | October 27, 2026
Assorted pharmaceutical pills, a medicine vial, and a syringe arranged on a laboratory bench.
3 Pharmaceutical Stocks That Offer Safety and Growth
By Chris Markoch | November 12, 2026
AbbVie stock logo

AbbVie NYSE:ABBV

$296.68 +1.70 (+0.57%)
As of 12:40 PM Eastern
This is a fair market value price provided by Massive. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Gilead Sciences stock logo

Gilead Sciences NASDAQ:GILD

$170.53 +0.80 (+0.47%)
As of 12:40 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$149.03 +1.85 (+1.26%)
As of 12:40 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

UnitedHealth Group stock logo

UnitedHealth Group NYSE:UNH

$405.14 +2.20 (+0.55%)
As of 12:40 PM Eastern
This is a fair market value price provided by Massive. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas